Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qiagen ( (QGEN) ) has provided an announcement.
Qiagen N.V. has announced a release of voting rights notification from the Netherlands Authority for the Financial Markets (AFM) concerning BlackRock, Inc. The notification, dated June 5, 2025, details BlackRock’s indirect holdings and voting rights in Qiagen, highlighting a capital interest of 9.98% and voting rights of 11.07%. This announcement reflects BlackRock’s significant stake in Qiagen, which could influence the company’s strategic decisions and impact stakeholder interests.
The most recent analyst rating on (QGEN) stock is a Hold with a $42.50 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company focuses on enabling customers to gain valuable insights from the building blocks of life, such as DNA, RNA, and proteins.
Average Trading Volume: 1,406,775
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.85B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.